Samantha Goodstal

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

Vincent A. de Weger, Maja J.A. de Jonge, Marlies H.G. Langenberg et al. · British Journal of Cancer · 2018 · 68 citations · Full text

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Francesca Vena, Eleonora Li Causi, Manuel Rodriguez‐Justo et al. · Clinical Cancer Research · 2015 · 58 citations

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models

Francesca Vena, Ruochen Jia, Arman Esfandiari et al. · Oncotarget · 2018 · 48 citations · Full text

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Angela Romanelli, Anderson Clark, Franck Assayag et al. · Molecular Cancer Therapeutics · 2012 · 45 citations · Full text

Breast Oncology, Medicine, Receptor Tyrosine Kinase +14

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

Eugenio Gaudio, Chiara Tarantelli, Ivo Kwee et al. · Annals of Oncology · 2016 · 32 citations · Full text

Tumor Biology, Lymphoid Neoplasia, Mek Inhibitor Pimasertib +11